BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus

American Journal of Transplantation

Volumn 5, Issue 6, 2005, Pages 1392-1396

  Lindenfeld, Jo Ann ^a   Simon, Shakar F ^a   Zamora, Martin R ^a   Cool, Carlyne D ^a   Wolfel, Eugene E ^a   Lowes, Brian D ^a   Ireland, Nancy ^a   Keller, Karin ^a   Frisk, Rhonda ^a   Stepien, Linda ^a   Cleveland, Joseph C ^a   Zolty, Ronald ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bronchiolitis obliterans organizing pneumonia; Heart transplantation; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFECTION COMPLICATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 20544468144     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00849.x     Document Type: Article

References (21)

1. Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
2. Snell GI, Lewey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540-546.
3. Groetzner J, Meiser B, Landwehr P et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568-574.
4. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
5. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109.
6. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
7. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
8. Champion L, Morelon E, Stern M et al. Sirolimus-related interstitial pneumonitts: report of 21 cases in renal transplant recipients. Am J Transplant 2004; 506.
9. Dominguez J, Mahalati K, Kiberd B et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244-1247.
10. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004; 4: 137-139.
11. Lennon A, Finan K, FitzGerald MX, McCormick PA. Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 2001; 72: 1166-1167.
12. Mahalati K, Murphy DM, West ML. Bronchiolitis obliterans and organinzing pneumonia in renal transplant recipients. Transplantation 2000; 69: 1531-1535.
13. Williams TJ, Lewey BJ, Russell PA, Milne DG, Snell GI. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22: 210-213.
14. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225-226.
15. Morelon E, Stern M, Israel-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787-790.
16. Pham PT, Pham PC, Danovitch GM et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215-1220.
17. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
18. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
19. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: 2694-7000.
20. Hodges TN, Torres FP, Marqueson J, Diercks M, Zamora MR. Community acquired respiratory viruses in lung transplant patients: indcidence and outcomes. J Heart Lung Transplant 2001; 20: 169-170.
21. Eisen HJ, Tuzcu EM, Dorent R et al for RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 Aug; 349: 829-830.